|
Delayed
Xetra
|
5-day change | 1st Jan Change | ||
| - EUR | -.--% |
|
-1.95% | -8.87% |
| 10/11/23 | Alvotech, Stada Get EU Panel Backing for Stelara Biosimilar | MT |
| 25/07/23 | Xbrane Biopharma and Stada consider options for ranibizumab | FW |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 62 | 31/08/2018 | |
Boris Döbler
DFI | Director of Finance/CFO | - | 31/12/2022 |
Miguel Fernandez
CTO | Chief Tech/Sci/R&D Officer | 61 | 31/12/2014 |
| Director | Title | Age | Since |
|---|---|---|---|
Jens Steegers
BRD | Director/Board Member | 46 | 03/06/2014 |
Eric Cornut
BRD | Director/Board Member | 69 | 25/08/2016 |
Günter von Au
CHM | Chairman | 75 | 26/09/2017 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -.--% | -1.95% | - | - | 5.73B | ||
| -1.61% | +1.72% | +38.30% | +106.93% | 1,043B | ||
| -0.76% | -0.84% | +35.21% | +62.70% | 618B | ||
| +0.39% | +4.81% | +17.81% | +83.77% | 481B | ||
| -0.29% | -0.99% | +64.79% | +37.06% | 351B | ||
| +1.59% | +3.53% | +21.90% | +42.67% | 338B | ||
| +1.11% | +2.22% | +11.54% | +34.94% | 269B | ||
| +1.69% | +1.77% | -6.65% | +11.27% | 244B | ||
| -1.37% | +0.04% | +38.29% | +52.33% | 220B | ||
| +0.17% | -0.27% | +24.40% | +96.82% | 182B | ||
| Average | +0.21% | +0.06% | +27.29% | +58.72% | 375.24B | |
| Weighted average by Cap. | -0.08% | +0.60% | +30.64% | +69.22% |
Employees
-
Sector
Pharmaceuticals
- Stock Market
- Stocks
- SAZ Stock
Select your edition
All financial news and data tailored to specific country editions
















